Pfizer ups offer for AstraZeneca again, to $119B
By LINDA A. JOHNSON - AP - 1 min ago
NEW YORK (AP) — U.S. drugmaker Pfizer said Sunday that it has raised its offer for British rival AstraZeneca by 15 percent over its last bid, making the stock-and-cash offer worth $118.8 billion, or 70.73 billion pounds.
Pfizer Makes Final Proposal to AstraZeneca
Business Wire - 2 hrs 34 mins ago
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
How Apple and Google Technology Can Help Fight Alzheimer's Disease
Leo Sun, The Motley Fool - Motley Fool - Sun May 18, 9:00AM CDT
Curing Alzheimer's disease, the 6th leading cause of death in the United States, remains one of the most elusive goals in modern medicine. Several high-profile efforts to clear away the buildup of brain plaques, one of the hallmarks of the...
The Dow's Dividend Giants: Yield Isn't Everything
Dan Caplinger, The Motley Fool - Motley Fool - Sun May 18, 8:05AM CDT
Dividends are important, and one of the best things about the Dow Jones Industrials is that every one of the 30 component stocks that make up the Dow pay a dividend. But when it comes to dividends, it is possible to have too much of a good thing...
Diabetic Neuropathy Market 2018: Eli Lilly and Co., Janssen Pharmaceuticals Inc., Pfizer Inc. and Other Vendors Analyzed at Sandlerresearch.org
PRWeb - Sat May 17, 1:31AM CDT
Diabetes is usually associated with progressive damage to the nervous system, which leads to disorders collectively known as diabetic neuropathy. Diabetic neuropathy is characterized by progressive damage to the neuronal myelin sheath, which slows down nerve conduction velocity. Axonal damage associated with diabetic neuropathy decreases nerve action potential below normal physiological level, which inhibits neuronal signal transmission. About 60 to 70 percent of the diabetic population develops neuropathy, with a considerable number of cases going undiagnosed during the initial years of progression. Disease management should start with the initial diagnosis of diabetes, from educating patients to giving them regular check-ups. Diabetic neuropathy treatment involves bringing blood glucose levels within the normal range to check for further nerve damage and also additional treatment to provide symptomatic relief. Alternative therapies, which help in managing pain, such as biofeedback, meditation, acupuncture or other relaxation techniques can also be used.
Pfizer seeks cancer drug nod
at Investor's Business Daily - Fri May 16, 6:01PM CDT
Top U.S. drugmaker by market value Pfizer (PFE) said it will file with the FDA for early approval of new breast cancer drug palbociclib. The filing will process as the drug finishes clinical trials. Pfizer completed a mid-stage trial and said it will...
Most active New York Stock Exchange-traded stocks
AP - Fri May 16, 5:06PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Fri May 16, 5:06PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Business Highlights
By The Associated Press - AP - Fri May 16, 4:01PM CDT
___
Pfizer Seeks Early Approval Of Breast Cancer Drug
at Investor's Business Daily - Fri May 16, 1:21PM CDT
Pfizer (PFE) ended weeks of speculation on Wall Street by announcing Friday that it will file for U.S. approval of its breast-cancer drug palbociclib before it finishes clinical trials. The palbociclib FDA filing will be based on the mid-stage...
Pfizer seeks early approval for breast cancer drug
By LINDA A. JOHNSON - AP - Fri May 16, 12:55PM CDT
TRENTON, N.J. (AP) — Pfizer Inc. said Friday that the Food and Drug Administration will let the drugmaker apply for approval of its heavily touted experimental breast cancer medicine based on midstage patient testing results.
Midday Glance: Pharmaceuticals companies
AP - Fri May 16, 12:33PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Today's Stocks Driving Success For The Health Care Sector
at The Street - Fri May 16, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Dow Today: Pfizer (PFE) Higher
at The Street - Fri May 16, 12:00PM CDT
The Dow component leading the way higher looks to be Pfizer (NYSE: PFE ), which is sporting a 30-cent gain (+1%) bringing the stock to $29.36.
The Dow Treads Water as Pfizer, General Electric Struggle With Mergers in Europe
Dan Caplinger, The Motley Fool - Motley Fool - Fri May 16, 11:30AM CDT
The Dow Jones Industrials was down just four points as of 12:30 p.m. EDT Friday. Even after two days of sharp declines, investors aren't willing to dive in to buy the dips as they have in the past. As some investors focus on the latest disclosure...
Pfizer To Submit Palbociclib New Drug Application With FDA Based On Final Results Of PALOMA-1
Business Wire - Fri May 16, 11:12AM CDT
Pfizer Inc. today announced that it will submit a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for palbociclib, combined with letrozole, as first-line systemic treatment of post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer. Pfizer expects to submit the NDA early in the third quarter of this year. This decision was based on discussions with the FDA regarding the final results of PALOMA-1, a randomized, Phase 2 trial comparing palbociclib plus letrozole versus letrozole alone in this population of patients.
Early Glance: Pharmaceuticals companies
AP - Fri May 16, 10:47AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Global Diabetic Neuropathic Foot Ulcers Therapeutics Clinical Trials Review 2014
M2 - Fri May 16, 9:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mg3g2w/diabetic) has announced the addition of the "Diabetic Neuropathic Foot Ulcers Global Clinical Trials Review, H1, 2014" report to their offering. Diabetic Neuropathic Foot Ulcers Global Clinical Trials Review, H1, 2014" provides data on the Diabetic Neuropathic Foot Ulcers clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Neuropathic Foot Ulcers. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Neuropathic Foot Ulcers. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Pfizer Inc. - Olympus Biotech Corporation - HealOr Ltd. (Inactive) - Regenerative Medicine Assets Limited - Johnson & Johnson - Derma Sciences, Inc. - Universidade Estadual Paulista - Department of Health, UK - Kermanshah University of Medical Sciences - The University of Birmingham - University of Miami - Washington University School of Medicine For more information visit http://www.researchandmarkets.com/research/mg3g2w/diabetic
FDA Approvals, Stock Price Updates, and Financial Results Release - Analyst Notes on Pfizer, Actavis, Pharmacyclics, Mallinckrodt and Salix Pharmaceuticals
PR Newswire - Fri May 16, 6:40AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Actavis plc (NYSE: ACT), Pharmacyclics, Inc. (NASDAQ: PCYC), Mallinckrodt PLC (NYSE: MNK) and Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2541-100free.